Clinical trials: Hyperplasia Prostatic
Benign Prostatic Hyperplasia, Prostatic Hyperplasia
Dutasteride 0.5mg For The Treatment Of Chinese Patients With Benign Prostatic Hyperplasia (BPH)
This randomized, double-blind, placebo-controlled, six-month parallel-group study assess efficacy and safety of dutasteride 0.5mg once daily in Chinese patients with Benign Prostatic Hyperplasia (BPH) , followed by a 12-month…
- Trial name
- NCT00527605
- Testing
- Dutasteride 0.5mg capsule
- Where
- 12 sites in China
- Volunteers
- 253 people
- Sponsor
- GlaxoSmithKline
Prostatic Hyperplasia
Evaluating the Impact of Early Versus Delayed 5 Alpha Reductase Inhibitor Treatment on the Risk of Emergent Surgery in Men With Benign Prostatic Hyperplasia
This retrospective study aims to assess the impact of early vs delayed 5-alpha-reductase inhibitor (5ARI) therapy in patients with BPH on alpha-blocker (AB) therapy and the risk of acute urinary retention (AUR), prostate-related…
- Trial name
- NCT01332487
- Testing
- 5ARI + AB
- Volunteers
- 4,068 people
- Sponsor
- GlaxoSmithKline
BPH, Prostate Hyperplasia
MRI Guided Transrectal Prostate Laser Ablation for Benign Prostatic Hypertrophy (BPH)
Over 100,000 BPH procedures are performed annually in the US. The purpose of this study is to evaluate the effectiveness of performing MRI guided transrectal laser ablation using a 980 nm laser (VisualaseTM by Medtronic, Inc., a…
- Conditions
- BPH, Prostate Hyperplasia, Urinary Frequency/Urgency
- Trial name
- NCT03131544
- Testing
- MRI Guided Transrectal Periuretheral Transitional Zone Ablation
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Prostate Laser Center, PLLC
Prostatic Hyperplasia
Dutasteride (GI198745) In Benign Prostatic Hyperplasia Subjects
This study will assess the efficacy and safety of GI198745 0.5mg given once daily for 52 weeks to Benign Prostatic Hyperplasia (BPH) patients.
- Trial name
- NCT00368979
- Testing
- Dutasteride
- Where
- 26 sites in Japan
- Volunteers
- 378 people
- Sponsor
- GlaxoSmithKline
Benign Prostatic Hyperplasia
A Comparison of Traditional and MOSES Laser Enucleation of the Prostate (MOLEP): A Prospective, Randomized, Double-blinded Control Trial A Comparison of Traditional and MOSES Laser Enucleation of the Prostate (MOLEP): A Prospective, Randomized, Double-blinded Control Trial
Holmium laser enucleation of the prostate (HOLEP) has proven to be efficacious and safe for the treatment of benign prostatic hypertrophy (BPH).
- Trial name
- NCT04263987
- Testing
- Moses laser enucleation of prostate
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University Medical Center
Uterine Fibroid, Arteriovenous Malformations
An Observational Study of Radial Access Embolization Procedures Using HydroPearl Microspheres
This registry study is designed to collect data on the procedural success and complication rates in real-world patients undergoing HydroPearl embolization procedures via radial access.
- Conditions
- Uterine Fibroid, Arteriovenous Malformations, Hypervascular Tumors, Benign Prostatic Hyperplasia
- Trial name
- RAVI Registry (NCT04272216)
- Testing
- Treatment with HydroPearl via radial access
- Where
- 6 sites in United States
- Volunteers
- 99 people
- Sponsor
- Terumo Medical Corporation
Prostatic Hyperplasia
Dutasteride in Enlarged Prostate Economic Assessment: A Retrospective Database Pooled Analysis of Early 5-alpha Reductase Inhibitor Use
This retrospective study aims to assess the economic impact of early initiation of 5-alpha-reductase inhibitor (5ARI) therapy in patients with enlarged prostate (EP) receiving 5ARI and alpha-blocker (AB) combination therapy.
- Trial name
- NCT01332435
- Testing
- 5ARI + AB
- Volunteers
- 6,896 people
- Sponsor
- GlaxoSmithKline
Benign Prostatic Hyperplasia
Effects of Tadalafil Once a Day for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia
The purpose of this study is to evaluate the function of the bladder and urethra during urinary storage or voiding in men with signs and symptoms of benign prostatic hyperplasia treated with either placebo or tadalafil.
- Trial name
- NCT00386009
- Testing
- Tadalafil
- Where
- 13 sites in United States, Greece and 1 more
- Volunteers
- 200 people
- Sponsor
- Eli Lilly and Company
Male Hypogonadism, Muscle Atrophy
5-Alpha Reductase and Anabolic Effects of Testosterone
The purpose of this study is to determine whether a higher-than-replacement dose of testosterone and finasteride can be combined to safely increase muscle strength in older men who have a low blood concentration of testosterone.
- Conditions
- Male Hypogonadism, Muscle Atrophy, Sarcopenia, Benign Prostate Hypertrophy
- Trial name
- NCT00475501
- Testing
- Testosterone Enanthate, Finasteride
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Benign Prostatic Hyperplasia
Dutasteride and Flex Dose of Tamsulosin on as Needed Basis, to Treat Benign Prostatic Hyperplasia
This study will investigate the efficacy and safety of treatment with Dutasteride (0.5mg), administered once daily for one year in combination with Tamsulosin (0.4mg), administered once daily for 3 months, followed by counseling…
- Trial name
- NCT00701779
- Testing
- Tamsulosin
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Siami, Paul F., M.D.
COVID-19, SARS-CoV2
Anti-Androgen Treatment for COVID-19
This study is intended to explore the possible protective role of anti-androgens in SARS-CoV-2 infection
- Conditions
- COVID-19, SARS-CoV2, Androgenetic Alopecia, Prostate Cancer
- Trial name
- NCT04446429
- Testing
- Proxalutamide, Standard of Care
- Where
- Brazil
- Volunteers
- 268 people
- Sponsor
- Applied Biology, Inc.
Benign Prostatic Hyperplasia
Study of Tadalafil Once-a-Day for 12 Weeks in Japanese Men With Benign Prostatic Hyperplasia Followed by an Open-Label Extension
This study is a randomized, double-blind, placebo-controlled, parallel-design to compare the efficacy and safety of tadalafil once-a-day dosing versus placebo for 12 weeks followed by an open-label extension to evaluate the…
- Trial name
- NCT00783094
- Testing
- Tadalafil 2.5 mg, Tadalafil 5 mg
- Where
- 6 sites in Japan
- Volunteers
- 422 people
- Sponsor
- Eli Lilly and Company
Lower Urinary Tract Symptoms, Benign Prostatic Hyperplasia
Long Term Study of Solifenacin Succinate and Tamsulosin Hydrochloride Oral Controlled Absorption System (OCAS) in Males With Lower Urinary Tract Symptoms
Clinical study to examine the safety, tolerability and efficacy of long-term combination therapy of tamsulosin and solifenacin in the treatment of males with lower urinary tract symptoms (LUTS) associated with benign prostatic…
- Trial name
- Neptune II (NCT01021332)
- Testing
- tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/6 mg), tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/9 mg)
- Where
- 70 sites in Austria, Belarus and 9 more
- Volunteers
- 1,067 people
- Sponsor
- Astellas Pharma Europe B.V.
Prostatic Hyperplasia
Clinical and Economic Outcomes of Patients Utilizing Combination Therapy for Enlarged Prostates: A Henry Ford Database Assessment
This retrospective study aims to assess the clinical and economic impact of early initiation of 5-alpha-reductase inhibitor (5ARI) therapy in patients with enlarged prostate (EP) receiving 5ARI monotherapy or combination therapy…
- Trial name
- NCT01386983
- Testing
- 5ARI, 5ARI + AB
- Volunteers
- 332 people
- Sponsor
- GlaxoSmithKline
Prostatic Hyperplasia
Determine the Bioequivalence of Two Formulations of Tamsulosin HCl Capsules in Fed Male.
Two tamsulosin HClformulations will be tested in fed state
- Trial name
- NCT02417844
- Testing
- tamsulosin (Astellas), Tamsulosin HCL
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Benign Prostatic Hyperplasia
To Evaluate the Safety and Performance of the ProstaCare Water Electrolysis System in Relieving Symptoms of BPH.
The purpose of this study is to evaluate the safety and performance of the ProstaCare System in relieving symptoms of urinary outflow obstruction secondary to benign prostatic hyperplasia.
- Trial name
- NCT02962674
- Testing
- prostaFix System
- Where
- 3 sites in New Zealand, Singapore
- Volunteers
- 49 people
- Sponsor
- ProstaCare Singapore Pte. Ltd.
Prostatic Hyperplasia, Lower Urinary Tract Symptoms
Bipolar Plasmakinetic TURP Vs Monopolar TURP in the Treatment of Lower Urinary Tract Symptoms
Randomized controlled trial with one-year follow-up comparing intra, peri and postoperative outcomes for plasmakinetic transurethral resection of prostate (PK-TURP) and monopolar transurethral resection of prostate (M-TURP) in…
- Conditions
- Prostatic Hyperplasia, Lower Urinary Tract Symptoms, Transurethral Resection of Prostate
- Trial name
- NCT03936244
- Testing
- Transurethral Resection of the Prostate (TURP)
- Where
- Spain
- Volunteers
- 100 people
- Sponsor
- Hospital Universitario de Fuenlabrada
Overactive Bladder
Extension Study of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia
This study will assess the long-term safety of vibegron when dosed up to 52 weeks in men with overactive bladder (OAB) symptoms on pharmacological therapy for Benign Prostatic Hyperplasia (BPH) who previously completed treatment…
- Trial name
- NCT04103450
- Testing
- Vibegron
- Where
- 35 sites in United States, Poland
- Volunteers
- 276 people
- Sponsor
- Urovant Sciences GmbH
Benign Prostatic Hyperplasia (BPH)
Prostatic Artery Embolization (PAE) for Treatment of Benign Prostatic Hyperplasia (BPH)
This is an open-labeled, non-randomized feasibility study to evaluate the safety of prostate artery embolization (PAE) for the treatment of lower urinary tract symptoms attributed to benign prostatic hyperplasia (BPH).
- Trial name
- NCT02026908
- Testing
- Prostate Artery Embolization
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Northwestern University
Benign Prostatic Hyperplasia
Research on Benefit of Umooze as Add- on Therapy in Benign Prostatic Hyperplasia
To evaluate the improvement in symptoms of Benign Prostatic Hyperplasia (BPH) according to the Prostate Symptom Score (IPSS) and Quality- of- Life (QoL) index after add- on therapy of Umooze twice daily administration for 56 days…
- Trial name
- NCT02313233
- Testing
- Umooze
- Where
- Taiwan
- Volunteers
- 41 people
- Sponsor
- Golden Biotechnology Corporation